SEATTLE – Iridius, a compliance-by-design AI platform for regulated workflow execution, today announced it has raised $8.6 million in seed funding led by Chalfen Ventures, with participation from Osage Venture Partners, Accenture Ventures, and Rock Yard Ventures.
The round brings together investors with deep experience in enterprise software, life sciences, and large-scale digital transformation, signaling strong conviction in both the team and the market opportunity.
Across regulated workflows, AI adoption is often blocked by fragmented systems, manual validation, and compliance processes that do not scale.
Iridius is building a new class of enterprise infrastructure that embeds compliance directly into AI systems as executable logic, enabling continuous enforcement and automatic evidence generation across the full lifecycle. It is designed to complement existing enterprise systems and AI platforms, not replace them.
This enables highly regulated enterprises to accelerate workflows, reduce validation overhead, and maintain continuous audit readiness, providing a foundation to reimagine business processes with AI.
AI Is Not the Problem. Execution Is.
Life sciences organizations are investing heavily in AI, but adoption is breaking down in the workflows that matter most. The challenge is not model performance. It is execution in regulated environments.
Compliance is still manual and retrospective. Workflows are fragmented, governance is disconnected, and evidence is generated after the fact. Most AI platforms were not designed for this reality and cannot meet the requirements of GxP environments.
As a result, AI initiatives stall before reaching production
Turning Compliance into a Strategic Advantage
Iridius embeds compliance directly into how systems operate.
The platform transforms regulatory standards and internal policies into structured, machine-readable logic and integrates that logic into enterprise workflows and applications. As systems run, compliance is enforced continuously, and evidence is generated automatically.
Compliance shifts from a bottleneck to a strategic advantage by enabling:
- Faster timelines through continuous compliance execution
- Lower cost by automating manual compliance work
- Reduced regulatory risk with continuous audit readiness
- The ability to scale AI from pilot to production
Investor Perspective
“When I met the Iridius team, it was immediately clear this wasn’t a typical seed-stage startup. CEO Mike Kropp arrived with six senior enterprise leaders. Their deep enterprise experience is matched by operational rigor and AI-native speed. The group works hard, holds itself to high standards, and takes enterprise customers seriously. It’s no surprise that Accenture, along with an advisory board of former pharma and life sciences CIOs, has joined me in backing Mike, Alistair, Mark, Spencer, and the exceptional Iridius team,” said Mike Chalfen, Founder of Chalfen Ventures.
“As AI compresses traditional sources of software differentiation, the advantage is shifting toward systems that can operate within real-world constraints like GxP compliance. In life sciences, that constraint has historically limited innovation and slowed adoption. Iridius is re-architecting this layer by making compliance native to execution, which we believe is critical to moving AI from pilot to production in regulated environments,” said Nate Lentz, Managing Partner at Osage Venture Partners.
“Our investment in Iridius is about giving life sciences organizations the ability to innovate without hesitation,” said Ray Pressburger, global life sciences lead at Accenture. “By embedding compliance into the core of AI, we’re helping accelerate clinical development, improve decision-making, and bring therapies to patients faster, all while meeting the rigorous expectations of regulators worldwide.”
Built by a Team That Has Scaled Enterprise Systems in Regulated Industries
The Iridius team brings deep experience from Microsoft, AWS, and OpenAI across global enterprise AI products, large-scale infrastructure, and regulated environments.
“AI isn’t failing because of its capability. It’s failing to scale because compliance isn’t built into how systems operate,” said Mike Kropp, CEO of Iridius. “We are building the infrastructure that makes AI deployable in regulated environments. By turning compliance into executable logic and embedding it directly into workflows, we enable enterprises to move faster, reduce risk, and take AI into production.”
Iridius has also assembled a Global and Technical Advisory Board of senior leaders from major pharmaceutical and life sciences organizations including Merck, Pfizer, J&J, Novartis, Allergan, and Bayer.
“In life sciences, it’s one thing to prove a concept and another to make it work in production under real regulatory constraints. That’s where most efforts fall down. What stood out about Iridius is the team’s experience building and shipping enterprise systems at scale, and their view of compliance not as overhead, but as something embedded into execution that becomes a real advantage,” said Clark Golestani, former President and CIO at Merck and Founder of K2 Access Fund.
